Mollica V.; Massari F.; Rizzo A.; Ferrara R.; Menta A.K.; Adashek J.J., Genomics and Immunomics in the Treatment of Urothelial Carcinoma, «CURRENT ONCOLOGY», 2022, 29, pp. 3499 - 3518 [articolo]Open Access
Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F., Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer, «EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT», 2022, 7, pp. 131 - 149 [articolo]
Rebuzzi S.E.; Rescigno P.; Catalano F.; Mollica V.; Vogl U.M.; Marandino L.; Massari F.; Mestre R.P.; Zanardi E.; Signori A.; Buti S.; Bauckneht M.; Gillessen S.; Banna G.L.; Fornarini G., Immune Checkpoint Inhibitors in Advanced Prostate Cancer: Current Data and Future Perspectives, «CANCERS», 2022, 14, Article number: 1245, pp. 1 - 16 [articolo]Open Access
Rizzo A.; Mollica V.; Santoni M.; Ricci A.D.; Gadaleta-Caldarola G.; Montironi R.; Massari F., Impact of clinicopathological features on immune-based combinations for advanced urothelial carcinoma: A meta-analysis, «FUTURE ONCOLOGY», 2022, 18, pp. 739 - 748 [articolo]
Marchese P.V.; Mollica V.; Tassinari E.; De Biase D.; Giunchi F.; Marchetti A.; Rosellini M.; Fiorentino M.; Massari F., Implications of TERT promoter mutations and telomerase activity in solid tumors with a focus on genitourinary cancers, «EXPERT REVIEW OF MOLECULAR DIAGNOSTICS», 2022, 22, pp. 997 - 1008 [articolo]
Rizzo A.; Mollica V.; Merler S.; Morelli F.; Sorgentoni G.; Oderda M.; Santoni M.; Massari F., Incidence of grade 3–4 adverse events, dose reduction, and treatment discontinuation in castration-resistant prostate cancer patients receiving PARP inhibitors: a meta-analysis, «EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY», 2022, 18, pp. 235 - 240 [articolo]
Rizzo A.; Dadduzio V.; Ricci A.D.; Massari F.; Di Federico A.; Gadaleta-Caldarola G.; Brandi G., Lenvatinib plus pembrolizumab: the next frontier for the treatment of hepatocellular carcinoma?, «EXPERT OPINION ON INVESTIGATIONAL DRUGS», 2022, 31, pp. 371 - 378 [articolo]
Santoni M.; Aurilio G.; Massari F.; Grande E.; Matrana M.R.; Rizzo M.; De Giorgi U.; Incorvaia L.; Martignetti A.; Molina-Cerrillo J.; Zabalza I.O.; Mollica V.; Rizzo A.; Battelli N.; Porta C., Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison, «CLINICAL GENITOURINARY CANCER», 2022, 20, pp. 285 - 295 [articolo]
Rizzo A.; Mollica V.; Santoni M.; Palmiotti G.; Massari F., Pathologic Complete Response in Urothelial Carcinoma Patients Receiving Neoadjuvant Immune Checkpoint Inhibitors: A Meta-Analysis, «JOURNAL OF CLINICAL MEDICINE», 2022, 11, Article number: 1038, pp. 1 - 8 [articolo]Open Access
Santoni M.; Rizzo A.; Mollica V.; Rosellini M.; Marchetti A.; Fragomeno B.; Battelli N.; Massari F., Pembrolizumab plus lenvatinib or axitinib compared to nivolumab plus ipilimumab or cabozantinib in advanced renal cell carcinoma: a number needed to treat analysis, «EXPERT REVIEW OF PHARMACOECONOMICS & OUTCOMES RESEARCH», 2022, 22, pp. 45 - 51 [articolo]
Massari F.; Mollica V., Personalizing immunotherapy for renal cell carcinoma: how far have we come?, «EXPERT OPINION ON BIOLOGICAL THERAPY», 2022, 22, pp. 1221 - 1225 [articolo]
Ricci A.D.; Rizzo A.; Mollica V.; Schiavina R.; Fiorentino M.; Brunocilla E.; Ardizzoni A.; Massari F., Platinum-based adjuvant chemotherapy for upper tract urothelial carcinoma: a change of paradigm? A meta-analysis of aggregate data, «ANTI-CANCER DRUGS», 2022, 33, pp. e61 - e68 [articolo]
Iacovelli R.; Ciccarese C.; Maruzzo M.; Atzori F.; Galli L.; Scagliarini S.; Massari F.; Verzoni E.; Cannella A.; Maratta M.G.; Caserta C.; Bimbatti D.; Deppieri F.M.; Dessi M.; Paolieri F.; Riccardi F.; Bracarda S.; De Giorgi U.; Basso U.; Tortora G.; Procopio G., Primary Tumor Shrinkage and the Effect on Metastatic Disease and Outcomes in Patients With Advanced Kidney Cancer With Intermediate or Poor Prognosis Treated With Nivolumab Plus Ipilimumab or Cabozantinib, «CLINICAL GENITOURINARY CANCER», 2022, 20, pp. 498 - 498.e9 [articolo]
Mollica V.; Massari F.; Andrini E.; Rosellini M.; Marchetti A.; Nuvola G.; Tassinari E.; Lamberti G.; Campana D., Prognostic Factors of Survival for High-Grade Neuroendocrine Neoplasia of the Bladder: A SEER Database Analysis, «CURRENT ONCOLOGY», 2022, 29, pp. 5846 - 5854 [articolo]Open Access
Santoni M.; Molina-Cerrillo J.; Massari F.; Montironi R.; Grande E., Re: Effect of Immunotherapy Time-of-day Infusion on Overall Survival Among Patients with Advanced Melanoma in the USA (MEMOIR): A Propensity Score-matched Analysis of a Single-centre, Longitudinal Study, «EUROPEAN UROLOGY», 2022, 81, pp. 623 - 624 [articolo]
